


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

A is an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocycl ring,  
or an optionally substituted bicyclic heterocycl group;

B is a phenyl or pyridyl ring;

Z is O, S, SO, or SO<sub>2</sub>;

R<sup>1</sup> is CO<sub>2</sub>R<sup>4</sup>, CN, CONR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>CO<sub>2</sub>R<sup>4</sup>, optionally substituted alkyl, optionally substituted alkenyl,  
optionally substituted SO<sub>2</sub>alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>CONR<sup>5</sup>R<sup>6</sup>, COalkyl, 2H-tetrazol-5-yl-  
methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

R<sup>2a</sup> and R<sup>2b</sup> independently are hydrogen, halogen, optionally substituted alkyl, optionally  
substituted alkoxy, CN, SO<sub>2</sub>alkyl, SR<sup>5</sup>, NO<sub>2</sub>, optionally substituted aryl, CONR<sup>5</sup>R<sup>6</sup> or  
optionally substituted heteroaryl;

R<sup>x</sup> is optionally substituted alkyl ~~wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR<sup>4</sup>, O and SO<sub>n</sub>, wherein n is 0, 1 or 2; or R<sup>x</sup> represents optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-heterocycl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-bicyclic heterocycl or optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-aryl;~~

R<sup>4</sup> is hydrogen or an optionally substituted alkyl;

R<sup>5</sup> is hydrogen or an optionally substituted alkyl;

R<sup>6</sup> is hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO<sub>2</sub>aryl, optionally substituted SO<sub>2</sub>alkyl, optionally substituted SO<sub>2</sub>heteroaryl, CN, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>aryl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>heteroaryl or COR<sup>7</sup>;

R<sup>7</sup> is hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

R<sup>8</sup> and R<sup>9</sup> independently are hydrogen, chloro, fluoro, CF<sub>3</sub>, C<sub>1-3</sub>alkoxy or C<sub>1-3</sub>alkyl;

Q<sup>a</sup> and Q<sup>b</sup> are independently selected from hydrogen and CH<sub>3</sub>;


wherein when A is a 6-membered ring the R<sup>1</sup> substituent and phenyl ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocycl group the R<sup>1</sup> substituent and phenyl ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

and derivatives thereof;

provided that the compound is not 2-benzyloxy[1,1';2',1"]terphenyl-4"-carboxylic acid[[.]]; or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein when A is a 6-membered ring, the R<sup>1</sup> substituent and phenyl ring are attached to carbon atoms 1,2-, or 1,3- relative to each other.
3. (Previously presented) A compound according to claim 1 wherein A is phenyl, pyridyl, or pyrazinyl.

4. (Currently Amended) A compound of formula (Ia):



(Ia)

wherein:

W, X, and Y each are CR<sup>12</sup> or N;

V is CR<sup>1</sup>, CR<sup>12</sup> or N;

wherein at least two of W, X, Y or V is CR<sup>12</sup>; and R<sup>12</sup> is independently selected from hydrogen, halogen, CN, optionally substituted CO<sub>2</sub>C<sub>1-6</sub>alkyl, CONR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>R<sup>6</sup>, optionally substituted NR<sup>5</sup>COC<sub>1-6</sub>alkyl, optionally substituted NR<sup>5</sup>COPhenyl, optionally substituted NR<sup>5</sup>COpiperidinyl, optionally substituted NR<sup>5</sup>COheterocycl, optionally substituted NR<sup>5</sup>SO<sub>2</sub>C<sub>1-6</sub>alkyl, OH, optionally substituted OC<sub>1-6</sub>alkyl, optionally substituted C<sub>1-6</sub>alkyl and NR<sup>10</sup>R<sup>11</sup>;

Q<sup>1</sup> and Q<sup>2</sup> each is CH, or one of Q<sup>1</sup> and Q<sup>2</sup> is N and the other is CH;

R<sup>1</sup> is CO<sub>2</sub>H, optionally substituted CONHSO<sub>2</sub>aryl, CH<sub>2</sub>CO<sub>2</sub>H, SO<sub>2</sub>NHCOR<sup>7</sup>, SO<sub>2</sub>NHCOC<sub>1-6</sub>alkyl or tetrazolyl and is positioned 1,2-, or 1,3- relative to the phenyl ring;

R<sup>2a</sup> and R<sup>2b</sup> are independently selected from hydrogen, halo, and CF<sub>3</sub>;

R<sup>x</sup> is optionally substituted C<sub>1-8</sub>alkyl, or R<sup>x</sup> represents optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-heterocycl or optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-phenyl wherein Q<sup>a</sup> and Q<sup>b</sup> are independently selected from hydrogen and CH<sub>3</sub>;

R<sup>4</sup> is hydrogen or an optionally substituted C<sub>1-6</sub>alkyl;

R<sup>5</sup> is hydrogen or an optionally substituted C<sub>1-6</sub>alkyl;

R<sup>6</sup> is hydrogen or an optionally substituted C<sub>1-6</sub>alkyl, optionally substituted SO<sub>2</sub>phenyl, optionally substituted SO<sub>2</sub>heterocycl group, CN, optionally substituted CH<sub>2</sub>phenyl or COR<sup>7</sup>;

R<sup>7</sup> is hydrogen, optionally substituted heteroaryl or optionally substituted phenyl;

R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen, chloro, fluoro, CF<sub>3</sub>, C<sub>1-3</sub>alkoxy or C<sub>1-3</sub>alkyl; and

R<sup>10</sup> and R<sup>11</sup> together with the nitrogen atom to which they are attached form a morpholine ring, a 5- or 6-membered lactam ring or a 5- or 6-membered cyclic sulphonamide[[.]] and derivatives thereof[[.]]; or a pharmaceutically acceptable salt thereof.

5. (Previously presented) A compound according to claim 1 wherein R<sup>x</sup> is optionally substituted C<sub>1-8</sub>alkyl, optionally substituted CH<sub>2</sub>phenyl, CH<sub>2</sub>pyridyl, or CH<sub>2</sub>thienyl.
6. (Previously presented) A compound according to claim 1 wherein R<sup>2b</sup> is positioned 1,4-relative to the Z substituent and 1,3- relative to the phenyl ring.
7. (Currently Amended) A compound selected from the ~~compounds of Examples 1-90 or a derivative thereof group consisting of:~~  
2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-3"-carboxylic acid;  
(2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-3"-yl)-acetic acid;  
(2-benzyloxy-5-chloro[1,1';2',1"]terphenyl-2"-yl)acetic acid;  
(2-benzyloxy-5-chloro[1,1';2',1"]terphenyl-4"-yl)acetic acid;  
5"-acetylamino-2-benzyloxy-5-chloro[1,1';2',1"]terphenyl-3"-carboxylic acid;  
2-benzyloxy-5-chloro-5"-propionylamino[1,1';2'1"]terphenyl-3"-carboxylic acid;  
2-benzyloxy-5-chloro-5"--(2-methylpropanoylamino)-[1,1';2',1"]terphenyl-3"-carboxylic acid;  
2-benzoyloxy-5"-butyrylarnino-5-chloro[1,1';2',1"]terphenyl-3"-carboxylic acid;  
2-benzyloxy-5-chloro-5"-[(1-phenyl-methanoyl)amino]-[1,1';2',1"]terphenyl-3"-carboxylic acid;  
2-benzyloxy-5-chloro-5"-methanesulfonylamino-[1,1';2',1"]terphenyl-3"-carboxylic acid  
5"-amino-2-benzyloxy-5-chloro[1,1';2',2"]-3"-carboxylic acid;  
2-benzyloxy-5"-butyrylarnino-5-trifluoromethyl[1,1';2',1"]terphenyl-3"-carboxylic acid-3-carboxylic acid;  
2-benzyloxy-4"-chloro[1,1';2',1"]terphenyl 2"-carboxylic acid;  
2-benzyloxy-5"-fluoro-[1,1';2',1"]terphenyl-2"-carboxylic acid;

2-benzyloxy-4"-fluoro-[1,1';2',1"]terphenyl-2"-carboxylic acid;

2"-benzyloxy-5-fluoro-[1,1';2',1"]terphenyl-3-carboxylic acid;

4"-amino-2-benzyloxy-[1,1';2',1"]terphenyl-3"-carboxylic acid;

5"-acetylamino-2-benzyloxy-[1,1';2',1"]terphenyl-2"-carboxylic acid;

2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-2"-carboxylic acid;

2-benzyloxy-[1,1';2',1"]terphenyl-3"-carboxylic acid;

2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-2"-carboxylic acid amide;

5-(2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-3"-yl)-1H-tetrazole;

N-[1-(2-benzyloxy-5-chloro-[1,1';2',1"]terphenyl-2"-yl)-methanoyl]-benzenesulfonamide;

2-benzyloxy-[1,1';2',1"]terphenyl-4"-sulfonic acid (1-phenyl-methanoyl)-amide;

2-benzyloxy-[1,1';2',1"]terphenyl-4"-sulfonic acid [1-(4-nitro-phenyl)-methanoyl]-amide;

2-benzyloxy-[1,1';2',1"]terphenyl-3"-sulfonic acid acetyl-amide;

5-chloro-2-(4-fluoro-benzyloxy) -[1,1';2',1"]terphenyl-3"-carboxylic acid;

5-chloro-2-(2,4-difluoro-benzyloxy) -[1,1';2',1"] terphenyl-3"-carboxylic acid;

5-chloro-2-(4-chloro-benzyloxy)-[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-(2-fluoro-4-chloro-benzyloxy) -[1,1';2',1"] terphenyl-3"carboxylic;

5-chloro-2-(pyridin-2-ylmethoxy) -[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-(pyridin-4-ylmethoxy) -[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-(pyridin-3-ylmethoxy) -[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-cyclohexylmethoxy -[1,1';2',1"]terphenyl-3"carboxylic acid;

5-chloro-2-(thiophen-3-ylmethoxy) -[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-(thiophen-2-ylmethoxy) -[1,1';2',1"] terphenyl-3"carboxylic acid;

5-chloro-2-cyclopentylmethoxy -[1,1';2',1"]terphenyl-3"carboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5-{[(methyloxy)carbonyl]-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

5-Chloro-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-2-carboxylic acid;

4-(Methoxy)-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-2-carboxylic acid;

2"-{[(2,4-Difluorophenyl)methyl]oxy}-4-(propanoylamino)-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;

2"-{[(2,4-Difluorophenyl)methyl]oxy}-4-[(2-methylpropanoyl)amino]-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;

5-(2-Oxo-1-pyrrolidinyl)-2"-[(phenylmethyl)oxy]-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3,5-dicarboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5-{[(2-methylpropyl)amino]carbonyl}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

6-[2"-{[(4-Fluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-2-biphenylyl]-2-pyrazinecarboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5-(propanoylamino)-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-[(Phenylmethyl)oxy]-5-(propanoylamino)-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-{[(2,4-Difluorophenyl)methyl]oxy}-5-(propanoylamino)-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-5-{[(methyloxy)acetyl]amino}-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-2"-[(phenylmethyl)oxy]-5-[(2-thienylacetyl)amino]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-2"-[(phenylmethyl)oxy]-5-{[(phenylmethyl)oxy]acetyl}amino)-1,1':2',1"-terphenyl-3-carboxylic acid;

5-[(1-Acetyl-4-piperidinyl)carbonyl]amino}-5"-chloro-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-5-[(phenylacetyl)amino]-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-5-{[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino}-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-5-[(3-methylbutanoyl)amino]-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Chloro-5-(glycylamino)-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-[(Phenylmethyl)oxy]-4-(propanoylamino)-1,1':2',1"-terphenyl-2-carboxylic acid;

4-[(2-Methylpropanoyl)amino]-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-2-carboxylic acid;

5-Cyano-2"-{[(2,4-difluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

5"-Bromo-5-cyano-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-3-carboxylic acid;

5-Cyano-2"-[(phenylmethyl)oxy]-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

5-(Aminocarbonyl)-2"-{[(4-fluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5-[(2-hydroxyethyl)amino]carbonyl}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

2"-{[(4-Fluorophenyl)methyl]oxy}-5-[(3-pyridinylmethyl)amino]carbonyl}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-3-carboxylic acid;

6-{5'-Chloro-2'-[(phenylmethyl)oxy]-2-biphenyl}-2-pyridinecarboxylic acid;

6-(5'-Chloro-2'-{[(4-fluorophenyl)methyl]oxy}-2-biphenyl)-2-pyridinecarboxylic acid;

6-(5'-Chloro-2'-{[(2,4-difluorophenyl)methyl]oxy}-2-biphenylyl)-2-pyridinecarboxylic acid;  
2-[2'-{[(4-Fluorophenyl)methyl]oxy}-5'-(trifluoromethyl)-2-biphenylyl]-4-pyridinecarboxylic acid;  
3-Amino-6-[2'-{[(4-fluorophenyl)methyl]oxy}-5'-(trifluoromethyl)-2-biphenylyl]-2-pyrazinecarboxylic acid;  
4-(Acetylamino)-2"-[(phenylmethyl)oxy]-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;  
4-(Acetylamino)-2"-{[(4-fluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;  
4-(Acetylamino)-2"-{[(2,4-difluorophenyl)methyl]oxy}-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;  
4-Methyl-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-2-carboxylic acid;  
2"-{[(2,4-Difluorophenyl)methyl]oxy}-4-methyl-5"--(trifluoromethyl)-1,1':2',1"-terphenyl-2-carboxylic acid;  
2-(4-Fluorobenzyl)oxy-5-fluoro[1,1',2,2']terphenyl-3"-carboxylic acid;  
2-(2,4-Difluorobenzyl)oxy-5-fluoro[1,1',2,2']terphenyl-3"-carboxylic acid;  
2'-{6-Chloro-3-[(phenylmethyl)oxy]-2-pyridinyl}-3-biphenylcarboxylic acid;  
5-Amino-2'-{6-chloro-3-[(phenylmethyl)oxy]-2-pyridinyl}-3-biphenylcarboxylic acid;  
4"-Chloro-2"-[(phenylmethyl)oxy]-1,1':2',1"-terphenyl-2-carboxylic acid; and  
6"Fluoro-2-benzyloxy- [1,1';2',1"]terphenyl-3"-carboxylic acid; or a pharmaceutically acceptable salt thereof.

8. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutical carrier and/or excipient.

9-10. (Canceled)


11. (Withdrawn) A method of treating an animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to claim 1.

12. (Withdrawn) A method of treating an animal subject suffering from a pain, or an inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to claim 1.

13. (Withdrawn) A method of treating an animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to claim 1.


14-16. (Canceled)

17. (Withdrawn) A process for the preparation of a compound of formula (I) as defined in claim 1 comprising:  
reacting a compound of formula (IV):



(IV)

wherein R<sup>8</sup>, R<sup>9</sup>, A, and R<sup>1</sup> are as hereinbefore defined above for a compound of formula (I), L<sup>1</sup> is a leaving group and P is an optional protecting group;  
with a compound of formula (III):



(III)

wherein  $R^{2a}$ ,  $R^{2b}$ , B, Z, and  $R^X$  are as hereinbefore defined above for a compound of formula (I); and where required converting:  
one group A to another group A, and/or  
one group  $R^X$  to another group  $R^X$ ;  
and where required carrying out the following optional steps in any order:  
effecting deprotection; and/or  
converting one group  $R^1$  to another group  $R^1$ ; and/or  
forming a derivative of the compound of formula (I) so formed.

18. (Canceled)

19. (Withdrawn) The method according to claim 11, wherein said animal is human.

20. (Withdrawn) The method according to claim 12, wherein said animal is human.

21. (Withdrawn) The method according to claim 13, wherein said animal is human.